Allergan Receives “Outperform” Rating from Zacks (AGN)
Allergan (NYSE:AGN)‘s stock had its “outperform” rating reiterated by Zacks in a report issued on Thursday, American Banking and Market News reports. They currently have a $138.00 target price on the stock. Zacks‘ price objective suggests a potential upside of 19.66% from the company’s current price.
Allergan (NYSE:AGN) traded up 1.88% during mid-day trading on Thursday, hitting $117.37. The stock had a trading volume of 2,353,162 shares. Allergan has a one year low of $81.33 and a one year high of $123.83. The stock’s 50-day moving average is $113.3 and its 200-day moving average is $96.91. The company has a market cap of $34.878 billion and a P/E ratio of 34.92.
Allergan (NYSE:AGN) last announced its earnings results on Tuesday, February 4th. The company reported $1.12 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.34 by $0.22. The company had revenue of $1.66 million for the quarter, compared to the consensus estimate of $1.65 million. During the same quarter in the previous year, the company posted $1.15 earnings per share. The company’s revenue for the quarter was up 14.4% on a year-over-year basis. On average, analysts predict that Allergan will post $5.45 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, March 21st. Investors of record on Friday, February 28th will be given a dividend of 0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.17%.
Several other analysts have also recently commented on the stock. Analysts at Citigroup Inc. upgraded shares of Allergan from a “neutral” rating to a “buy” rating in a research note to investors on Tuesday. They now have a $130.00 price target on the stock, up previously from $95.00. Separately, analysts at SunTrust upgraded shares of Allergan from a “neutral” rating to a “buy” rating in a research note to investors on Friday, January 17th. They now have a $150.00 price target on the stock, up previously from $94.00. Finally, analysts at Morgan Stanley reiterated an “equal weight” rating on shares of Allergan in a research note to investors on Wednesday, January 15th. They now have a $94.00 price target on the stock. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $117.05.
Allergan, Inc, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.